BioNexus Gene Lab Corp (NASDAQ:BGLC)
| Market Cap | 3.12M-76.7% |
| Revenue (ttm) | 3.13M-67.3% |
| Net Income | -2.58M+12.2% |
| EPS | -1.26+22.7% |
| Shares Out | 2.42M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 431 |
| Open | 1.35 |
| Previous Close | 1.34 |
| Day's Range | 1.25 - 1.35 |
| 52-Week Range | 1.07 - 5.89 |
| Beta | 2.20 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
Insiders here have filed 5 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About BGLC
BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala Lumpur, Malaysia, conducts business through two primary subsidiaries. Its subsidiary, Chemrex Corporation Sdn. Bhd., specializes in the wholesale distribution of chemical raw material products across Malaysia, Indonesia, Vietnam, and other nations within Southeast Asia. These essential chemicals are utilized in the manufacturing of a wide array of products, including handrails, bench tops, components for the automotive and aerospace industries, cleanroom panels, and various instruments. Additionally, through its other subsidiary, BioNexus Gene Lab Sdn. Bhd., the company is involved in the development and provision of non-invasive liquid biopsy tests, designed for the early detection of biomarkers.
$BGLC stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in BGLC holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by BGLC's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
BGLC Estimated quarterly lobbying spending
Source: U.S. Senate LDA
BGLC Revenue by Segment or Geography
| Segment | Revenue | % of All |
|---|---|---|
| Reversal of expected credit losses | $118.13K | 25.07% |
| Myanmar | $99.00K | 21.01% |
| By Business Unit | $99.00K | 21.01% |
| By Country | $99.00K | 21.01% |
| Fair value gain on investments in equity securities | $28.26K | 6.00% |
| Dividend income | $17.56K | 3.73% |
| Others | $8.39K | 1.78% |
| Gain from foreign exchange | $1.79K | 0.38% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New BGLC patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to BGLC from public contracts
Source: USAspending.gov
BGLC Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from BGLC’s recent data — informational, not investment advice